NASDAQ : BCRX

BioCryst Pharmaceuticals, Inc. — Key statistics

Healthcare · Drug Manufacturers - Specialty & Generic · United States

Last price 8.47 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 2.16B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Key statistics

Valuation

Measure	Value
Market Cap	2.16B
Enterprise Value	2.65B

Dates

Measure	Value
Earnings Date	Nov 4, 2026
Ex-Dividend Date	n/a

Shares

Measure	Value
Current Share Class	255.54M
Shares Outstanding	255.54M
Shares Change (YoY)	+10.24%
Shares Change (QoQ)	+9.46%
Owned by Insiders (%)	0.90%
Owned by Institutions (%)	92.40%
Float	222.32M

Ratios

Measure	Value
PE Ratio	n/a
Forward PE	16.33
PS Ratio	2.30
Forward PS	3.14
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	5.80
P/OCF Ratio	5.75
PEG Ratio	n/a

Evratios

Measure	Value
EV / Earnings	n/a
EV / Sales	2.82
EV / EBITDA	6.12
EV / EBIT	6.17
EV / FCF	7.09

Financialposition

Measure	Value
Current Ratio	2.32
Quick Ratio	2.22
Debt / Equity	n/a
Debt / EBITDA	1.92
Debt / FCF	2.24
Interest Coverage	5.70

Financialefficiency

Measure	Value
Return on Equity (ROE)	n/a
Return on Assets (ROA)	52.86%
Return on Invested Capital (ROIC)	138.77%
Return on Capital Employed (ROCE)	122.99%
Weighted Average Cost of Capital (WACC)	7.22%
Revenue Per Employee	$2.16M
Profits Per Employee	-$884,306
Employee Count	435
Asset Turnover	1.85
Inventory Turnover	38.32

Taxes

Measure	Value
Income Tax	3.49M
Effective Tax Rate	n/a

Stockprice

Measure	Value
Beta (5Y)	0.55
52-Week Price Change	+15.87%
50-Day Moving Average	8.63
200-Day Moving Average	8.75
Relative Strength Index (RSI)	54.82
Average Volume (20 Days)	4,911,854

Shortselling

Measure	Value
Short Interest	26.60M
Short Previous Month	27.49M
Short % of Shares Out	10.41%
Short % of Float	11.96%
Short Ratio (days to cover)	4.97

Incomestatement

Measure	Value
Revenue	940.61M
Gross Profit	727.92M
Operating Income	429.25M
Pretax Income	-381.19M
Net Income	-384.67M
EBITDA	433.05M
EBIT	429.25M
Loss Per Share	-$1.68

Balancesheet

Measure	Value
Cash & Cash Equivalents	352.57M
Total Debt	836.65M
Net Cash	-484.07M
Net Cash Per Share	-$1.89
Equity (Book Value)	-454.29M
Book Value Per Share	-1.78
Working Capital	275.84M

Cashflow

Measure	Value
Operating Cash Flow	376.14M
Capital Expenditures	-2.76M
Depreciation & Amortization	3.80M
Net Borrowing	127.48M
Free Cash Flow	373.38M
FCF Per Share	$1.46

Margins

Measure	Value
Gross Margin	77.39%
Operating Margin	45.63%
Pretax Margin	-40.53%
Profit Margin	-40.90%
EBITDA Margin	46.04%
EBIT Margin	45.63%
FCF Margin	39.70%

Dividends

Measure	Value
Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
FCF Payout Ratio	n/a
Buyback Yield	-10.24%
Shareholder Yield	-10.24%
Earnings Yield	-19.79%
FCF Yield	17.25%

Analystforecasts

Measure	Value
Price Target	$20.55
Price Target Difference	142.62%
Analyst Consensus	Buy
Analyst Count	11
Revenue Growth Forecast (3Y)	-1.73%
EPS Growth Forecast (3Y)	25.01%

Stocksplits

Measure	Value
Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Measure	Value
Altman Z-Score	0.52
Piotroski F-Score	6

Fairvalue

Measure	Value
Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a